TY - JOUR
T1 - MTOR inhibitors in cancer therapy
AU - Zaytseva, Yekaterina Y.
AU - Valentino, Joseph D.
AU - Gulhati, Pat
AU - Mark Evers, B.
PY - 2012/6/1
Y1 - 2012/6/1
N2 - The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer.
AB - The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer.
KW - Cancer
KW - Cancer therapy
KW - Drug resistance
KW - MTOR
UR - http://www.scopus.com/inward/record.url?scp=84858082548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858082548&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2012.01.005
DO - 10.1016/j.canlet.2012.01.005
M3 - Review article
C2 - 22261336
AN - SCOPUS:84858082548
SN - 0304-3835
VL - 319
SP - 1
EP - 7
JO - Cancer Letters
JF - Cancer Letters
IS - 1
ER -
